The all-stock deal values Personalis at $16.25 per share, a 6% premium to Friday’s close, expanding Tempus’ minimal residual disease testing portfolio.
Tempus AI will acquire cancer-monitoring firm Personalis in a $1.5 billion stock deal. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday’s closing price and 28% above the 30-day volume-weighted average.
The transaction, structured as all-stock with an option for up to 50% cash, follows a November 2023 partnership. Personalis’ NeXT Personal test, which tracks circulating tumor DNA, has Medicare coverage for three indications and delivered 10,384 clinical tests in Q2, up 33% sequentially.
Shares of Tempus fell over 8% Monday, while Personalis dropped 11.5%. The deal is expected to close in late 2026.